CareDx Inc (NASDAQ:CDNA)

17.28
Delayed Data
As of Aug 17
 +0.21 / +1.23%
Today’s Change
1.70
Today|||52-Week Range
18.05
+135.42%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$612.8M

Company Description

CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function and AlloSure, which is a donor-derived cell free DNA test. The firm operates through two segments: Post-Transplant and Pre-Transplant. The Post-Transplant segment is engages in development of diagnostic solutions for transplant patients. The Pre-Transplant segment develops, manufactures, markets and sells products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Contact Information

CareDx, Inc.
3260 Bayshore Boulevard
Brisbane California 94005
P:(415) 287-2300
Investor Relations:

Employees

Shareholders

Other institutional54.09%
Mutual fund holders21.41%
Individual stakeholders21.19%

Top Executives

Peter K. MaagPresident, Chief Executive Officer & Director
Mitchell J. NellesChief Operating Officer
Michael BellChief Financial Officer
James P. YeeChief Medical Officer & Executive Vice President
Anders Eric KarlssonChief International Business Officer